We propose that PD-L2 plays an important role in evading antitumor immunity as well as PD-L1, suggesting that PD-1/PD-L2 blockade must be considered for optimal immunotherapy in PD-L2-expressing cancers, such as HNSCC, RCC, and LUSC. Here, PDCD1 is linked to head and neck squamous cell carcinoma.